for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion
Renata Gallagher



A Phase 1/2, open-label dose-finding safety study of single ascending doses of DTX301 in adults with late-onset OTC Deficiency

Official Title

A Phase 1/2, Open-Label Safety and Dose-Finding Study of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Adults With Late-Onset OTC Deficiency


This is a Phase 1/2, open-label, single arm, multicenter, safety and dose finding study of DTX301 in adults with late-onset OTC deficiency. The primary objective of the study is to determine the safety of single IV doses of DTX301.

Eligible subjects will receive a single IV infusion of DTX301. Dose escalation will be conducted according to a model that uses the collected data to predict the safety profile of the dose in order to determine the optimal biological dose (OBD). The decision to proceed to the next dose cohort will be made after the data monitoring committee (DMC) has evaluated the safety data for all subjects in a dosing cohort.

Subjects will be followed for 52 weeks after dosing. After completion of this study, subjects will be asked to enroll in a 4-year extension study to evaluate the long term (a total of 5 years) safety and efficacy of DTX301.

This study was previously posted by Dimension Therapeutics, which has been acquired by Ultragenyx.


Ornithine Transcarbamylase (OTC) Deficiency Gene Transfer OTC Deficiency Urea Cycle Disorder Ornithine Carbamoyltransferase Deficiency Disease Prednisone Prednisolone scAAV8OTC Oral prednisone Dose 1: 2.0 × 10^12 GC/kg Dose 2: 6.0 × 10^12 GC/kg Dose 3: 1.0 × 10^13 GC/kg Dosing Process Optimization


You can join if…

Open to people ages 18 years and up

  1. Males and females ≥18 years of age with documented diagnosis of late onset (defined as first manifestation of signs and symptoms at ≥1 month of age) OTC deficiency, confirmed via enzymatic, biochemical, or molecular testing
  2. Documented history of ≥1 symptomatic hyperammonemia event with ammonia ≥100 µmol/L.
  3. Subject's OTC deficiency is stable as evidenced by either a) no clinical symptoms of hyperammonemia OR b) an ammonia level <100 µmol/L within the 4 week period preceding the Screening visit.
  4. On stable dose of ammonia scavenger therapy for ≥4 weeks.
  5. Males and all females of childbearing potential must be willing to use effective contraception at the time of administration of gene transfer and for the 52 weeks following administration of DTX301

You CAN'T join if...

  1. Screening or Baseline (Day 0) ammonia level ≥100 µmol/L or signs and symptoms indicative of hyperammonemia during the 4-week period preceding Day 0
  2. Liver transplant, including hepatocyte cell therapy/transplant.
  3. History of liver disease
  4. Serum creatinine >2.0 mg/dL.
  5. Participation in another investigational medicine study (including another gene transfer trial) within 3 months of Screening
  6. History of a malignancy for which the subject has received treatment in the past 2 years except for prostate cancer treated with watchful waiting or surgically removed non-melanoma skin cancer.


  • University of California San Francisco accepting new patients
    San Francisco California 94158 United States
  • Ronald Reagan University of Califonria Los Angeles Medical Center accepting new patients
    Los Angeles California 90095 United States

Lead Scientist

  • Renata Gallagher
    Professor, Pediatrics. Authored (or co-authored) 37 research publications


accepting new patients
Start Date
Completion Date
Ultragenyx Pharmaceutical Inc
Phase 1/2
Study Type
Last Updated